Retatrutide vs Semaglutide vs Tirzepatide

The three most researched metabolic peptides for fat loss in 2026 operate on fundamentally different receptor strategies. This comparison breaks down the mechanisms, clinical data, and trade-offs between the single-agonist (semaglutide), dual-agonist (tirzepatide), and triple-agonist (retatrutide) approaches.

Head-to-Head Comparison

Why Retatrutide Is the Stack Choice

The Clavicular Ascension Stack uses retatrutide rather than semaglutide or tirzepatide for one critical reason: the glucagon receptor. GCGR activation stimulates hepatic fat oxidation and energy expenditure directly — a fat-burning pathway that single and dual agonists lack entirely. This means retatrutide drives body recomposition from both sides: reducing caloric intake (GLP-1R appetite suppression) while simultaneously increasing energy expenditure (GCGR fat oxidation).

When paired with the stack's GH axis compounds (HGH + IGF-1 LR3 + CJC-1295) and cortisol control (Anavar), retatrutide enables aggressive fat loss while preserving lean tissue — the core research goal of body recomposition protocols.

Semaglutide: The Established Single Agonist

Semaglutide (marketed as Ozempic/Wegovy) targets GLP-1R exclusively. Its mechanism centers on appetite suppression via hypothalamic signaling and delayed gastric emptying. With the longest clinical track record and FDA approval, semaglutide is the most studied GLP-1 drug — but its single-receptor approach means no direct effect on fat oxidation or GIP-mediated insulin sensitivity.

Tirzepatide: The Dual Agonist Middle Ground

Tirzepatide (Mounjaro/Zepbound) adds GIPR activation to the GLP-1R base, creating a "twincretin" effect. GIP receptor activation enhances glucose-dependent insulin secretion and improves pancreatic beta-cell function. Clinical data shows slightly better weight loss than semaglutide (~20–22% vs ~15–17%), suggesting the dual pathway adds meaningful efficacy.

Retatrutide: The Triple Agonist

Retatrutide adds the glucagon receptor (GCGR) as a third target. GCGR activation has several distinct effects not available through GLP-1 or GIP alone: stimulation of hepatic glycogenolysis and gluconeogenesis (increasing energy expenditure), direct activation of brown adipose tissue thermogenesis, enhanced hepatic lipid oxidation, and increased satiety signaling. Phase 2 data showed the highest weight reduction range (up to 24%) of any metabolic peptide tested to date.

Full Retatrutide research guide → · Best fat loss stack guide →